SCHEMBL239299

SCHEMBL239299

C[C@H](N)C(=O)Oc1ccc(N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.48
TDP1 Q9NUW8 6/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
BLM P54132 1/20 0.42
CASP6 P55212 1/20 0.42
GFER P55789 1/20 0.42
MAPK1 P28482 1/20 0.41
PARP10 Q53GL7 1/20 0.41
CYP3A4 P08684 6/20 0.40
CYP1A2 P05177 3/20 0.40
F2 P00734 2/20 0.40
PRSS1 P07477 2/20 0.40
PRSS2 P07478 2/20 0.40
PRSS3 P35030 2/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28267944 0.98 ELANE (0.47) ELANETDP1KDM4EGLAGAA
SCHEMBL15679080 0.92 ELANE (0.55) ELANEMAPTPARP10CYP3A4CYP1A2
SCHEMBL23493150 0.92 ELANE (0.55) ELANEMAPTPARP10CYP3A4CYP1A2
Hydrochloric Acid SCHEMBL30184762 0.90 ELANE (0.53) ELANEMAPTPARP10CYP3A4CYP1A2
SCHEMBL20472709 0.86 SMN1; SMN2 (0.50) ELANEKDM4EMAPTTHRBPRSS1
SCHEMBL4683823 0.86 ELANE (0.66) ELANETDP1KDM4EGLAGAA
SCHEMBL3128225 0.84 ELANE (0.48) ELANETDP1KDM4EGLAGAA
Hydrochloric Acid SCHEMBL27456547 0.84 ELANE (0.63) ELANETDP1KDM4EGLAGAA
SCHEMBL15679089 0.84 ELANE (0.48) ELANETDP1KDM4EGLAGAA
SCHEMBL3199570 0.84 ELANE (0.48) ELANEGAAPARP10CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339569-A1 CARBONIC ANHYDRASE IX LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-11-06 US claimed
EP-4448544-A2 CARBONIC ANHYDRASE IX LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-10-23 EP claimed
WO-2023111350-A2 CARBONIC ANHYDRASE IX LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-06-22 WO claimed
US-20210206835-A1 Self-Assembling Collagen-Like Polypeptides for Applications and Uses Related Thereto NATIONAL SCIENCE FOUNDATION 2021-07-08 US claimed
EP-3788149-A1 A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION Ambrx, Inc. (US) 2021-03-10 EP claimed
US-20190135865-A1 AGONIST AGENTS OF CD47 INDUCING PROGRAMMED CELL DEATH AND THEIR USE IN THE TREATMENTS OF DISEASES ASSOCIATED WITH DEFECTS IN PROGRAMMED CELL DEATH SORBONNE UNIVERSITE (FR) 2019-05-09 US claimed
EP-3454880-A1 AGONIST AGENTS OF CD47 INDUCING PROGRAMMED CELL DEATH AND THEIR USE IN THE TREATMENTS OF DISEASES ASSOCIATED WITH DEFECTS IN PROGRAMMED CELL DEATH SORBONNE UNIVERSITE (FR) 2019-03-20 EP claimed
WO-2017194634-A1 AGONIST AGENTS OF CD47 INDUCING PROGRAMMED CELL DEATH AND THEIR USE IN THE TREATMENTS OF DISEASES ASSOCIATED WITH DEFECTS IN PROGRAMMED CELL DEATH UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2017-11-16 WO claimed
US-20160257643-A1 AMINO ACID DERIVATIVES AND ABSORBABLE POLYMERS THEREFROM BEZWADA BIOMEDICAL LLC (US) 2016-09-08 US claimed
CN-104470524-A Ghrelin receptor agonists for the treatment of achlorhydria RAQUALIA PHARMA INC 2015-03-25 CN claimed
EP-2262763-A2 COMPOUNDS AND METHODS OF TREATING OBESITY Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2010-12-22 EP claimed
CN-101674853-A Amino acid lipids and uses thereof NASTECH PHARM CO 2010-03-17 CN claimed
WO-2009109973-A2 COMPOUNDS AND METHODS OF TREATING OBESITY YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2009-09-11 WO claimed
CN-100423772-C Stabilization of pharmaceutical protein formulations with small peptides BAXTER INT (US) 2008-10-08 CN claimed
CN-101060885-A Treating depressive disorders with carbonic anhydrase activators BRNI NEUROSCIENCES INST (US) 2007-10-24 CN claimed
CN-1791420-A Treatment of T-cell mediated diseases DMI BIOSCIENCES INC (US) 2006-06-21 CN claimed
CN-1674899-A Use of IkappaB-kinase inhibitors in pain therapy AVENTIS PHARMA GMBH (DE) 2005-09-28 CN claimed
CN-1549722-A Anti-cancer and wound healing compounds 金伯利-克拉克环球有限公司 2004-11-24 CN claimed
EP-0225503-B1 RESOLUTION SYSTEM YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) 1989-08-02 EP claimed
EP-0225503-A1 Resolution system YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) 1987-06-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257643-A1 AMINO ACID DERIVATIVES AND ABSORBABLE POLYMERS THEREFROM SRRM2, SLC7A1, BCAT2 ELANE 3207/4885TDP1 1961/4885KDM4E 2679/4885
US-20190135865-A1 AGONIST AGENTS OF CD47 INDUCING PROGRAMMED CELL DEATH AND THEIR USE IN THE TREATMENTS OF DISEASES ASSOCIATED WITH DEFECTS IN PROGRAMMED CELL DEATH CD47, BID, CD274 ELANE 2006/4885TDP1 2790/4885KDM4E 2174/4885
US-20250339569-A1 CARBONIC ANHYDRASE IX LIGANDS CA9, CA13, CA4 ELANE 2918/4885TDP1 4334/4885KDM4E 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.